Fertility, pregnancy, and GLP-1 questions

Wegovy and Zepbound both carry warnings against use during pregnancy. Here is what the prescribing information actually states, where the evidence is thin, and why this conversation belongs with a specialist.

A prescribing label, sometimes called the package insert or PI, is the official FDA-reviewed document that accompanies every approved medication. It is the authoritative starting point for understanding what a drug is approved for, what risks have been identified, and what precautions apply. When a label is updated, it reflects a regulatory decision, not a marketing choice. Both the Wegovy and Zepbound labels include clear language about pregnancy:

Wegovy (semaglutide): The label states that the medication may cause fetal harm and advises that it should be discontinued when pregnancy is recognized.

Zepbound (tirzepatide): The label carries the same core warnings: potential fetal harm and discontinuation upon recognition of pregnancy.

Both labels also carry a contraindication for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is not a pregnancy-specific warning, but it is part of the overall risk profile for both medications. One clarification worth making: a prescribing label is a regulatory floor, not a personalized clinical recommendation. It tells prescribers and patients what is known and what precautions apply across a broad population. What it means for any individual patient is a question for that patient's clinician.

The regulatory framework behind these labels is worth understanding briefly. In 2015, the FDA replaced an older letter-based pregnancy safety system (the familiar A, B, C, D, X categories) with the Pregnancy and Lactation Labeling Rule, commonly called the PLLR. The older letter system was widely criticized for being oversimplified and sometimes misleading. The PLLR was designed to give prescribers and patients more structured, consistent, and nuanced information. Under the PLLR, drug labels must include a summary of what is known about risks during pregnancy and lactation, the data behind those risk assessments (including whether they come from animal studies, human studies, or both), and contact information for any pregnancy exposure registry associated with the drug. The PLLR does not assign a safety verdict. It requires disclosure of what is known and what is not. That distinction matters: a label that says "may cause fetal harm based on animal data" is not the same as one that says "proven safe" or "proven harmful in humans." It means the evidence base is limited, and the precautionary position is to avoid use.

Both the Wegovy and Zepbound labels reference animal reproductive toxicology studies suggesting potential fetal harm at certain exposure levels. Animal studies of this kind are a standard part of drug development. When it is not ethical or feasible to conduct controlled trials in pregnant humans, which is almost always the case for new medications, researchers use animal models to look for signals of reproductive or developmental harm. These studies are designed to detect problems, not to confirm safety. Both labels acknowledge the key caveat: animal study findings do not translate directly to human risk. Different species metabolize drugs differently. Doses used in animal studies may not reflect typical human exposure. The biological mechanisms involved may not be the same. In practice, the animal data raised enough concern to warrant precautionary label language, but it does not tell us what the actual risk to a human fetus would be. That question remains genuinely unanswered. No robust human clinical trial data on GLP-1 receptor agonist use during pregnancy currently exists. The guidance in both labels is based on animal data and theoretical risk reasoning. This is not a gap that any article can fill.

Under the PLLR, manufacturers are required to include pregnancy exposure registry information in their labels when a registry exists. Both Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound) maintain such registries. A pregnancy exposure registry collects outcomes data from people who were exposed to a drug during pregnancy, often unintentionally, before they knew they were pregnant. Over time, these registries can generate real-world human data about what actually happens when a drug is used during pregnancy. That is the goal. The current reality: both registries are ongoing, and no published conclusions from either are available from the sources reviewed for this article. The data is being collected, but it has not yet produced the kind of evidence that would allow anyone to make confident statements about human fetal risk. The absence of published registry data is not reassurance. It is a gap. Decisions made today are being made without that evidence base, which is still being built. Whether enrollment in a registry is appropriate for your situation is a question to raise with your clinician.

One of the most common questions people ask is: if I want to get pregnant, how far in advance should I stop my GLP-1 medication? This article cannot give you a number, and it would be misleading to try. Both prescribing labels advise discontinuing the medication when pregnancy is recognized. Neither provides a specific pre-conception discontinuation timeline. Clinical discussions about stopping timelines often reference a drug's half-life, meaning how long it takes for the body to clear the medication, and the concept of a washout period. Semaglutide and tirzepatide both have relatively long half-lives compared to many medications, which is relevant to this question. But translating half-life data into a specific pre-conception recommendation requires individualized clinical judgment that accounts for your health history, your reasons for taking the medication, and your reproductive plans. No evidence-based universal standard for pre-conception discontinuation appears in the prescribing information reviewed here. A specific timeline is precisely the kind of question that belongs in a conversation with your OB-GYN, reproductive endocrinologist, or prescribing clinician.

The questions below are a practical starting point for a conversation with your OB-GYN, reproductive endocrinologist, or prescribing clinician. They are not medical advice. A clinician who knows your full history will ask and answer questions this article cannot anticipate.

If you are planning to conceive

"I am currently taking [Wegovy/Zepbound] and am planning to conceive. When and how should I stop, given my specific situation?"

"What does my health history mean for how we approach this transition?"

"Who should be coordinating my care: you, my prescriber, or a specialist?"

If you have already become pregnant

"What monitoring or follow-up would you recommend given that I was on this medication?"

"Are there pregnancy exposure registries I should know about, and does my situation warrant enrollment?"

Regarding ongoing care

"What weight management support is appropriate for me during pregnancy, given my history?"

"What should I watch for, and when should I contact you?"

These are starting points. The right questions for your situation may be different.

This article reflects prescribing label language and the FDA regulatory framework as of the sources reviewed. Labels are updated periodically; verify current language with your pharmacist or clinician rather than relying on any article. No human clinical trial safety data on GLP-1 use during pregnancy is available to summarize, because none currently exists in the sources reviewed. This article does not cover alternative weight management strategies during pregnancy. That guidance requires individualized clinical input from providers aligned with current obstetric standards of care. General health content cannot account for individual medical history, comorbidities, reproductive goals, or the full clinical picture that a specialist would consider.